This Belgian Biotech Could Speed Up Diagnoses for Neurodegenerative Diseases

Today we’re in Ghent, Belgium, home to several successful biotechs, including Ablynx, to visit ADx Neurosciences. The biotech specializes in biomarker assays for the detection of neurodegenerative diseases. 

Visit our map to check out some more of Europe’s exciting biotech companies.

Mission: Founded in 2011, ADx Neurosciences focuses on the development of antibodies to detect biomarkers in the diagnosis of neurodegenerative conditions from Alzheimer’s and Parkinson’s to traumatic brain injury. The anitbodies identify molecules involved in neurodegenerative diseases such as amyloid beta and α-synuclein, which could help diagnose diseases before the symptoms appear.

ADx is developing assays for its biomarkers in collaboration with in vitro diagnostics companies. The technology can then be used to help pharmaceutical companies determine which drugs are worth moving into clinical trials from preclinical studies.

Comment: The potential of ADx’s technology to expedite the diagnosis of neurodegenerative conditions comes at an opportune time, as biotechs increasingly consider whether targeting the disease early is the key to getting treatments to work.

Biomarkers do have limitations, such as the high cost of CNS biomarkers or invasive procedures associated with them. However, the technology could improve diagnosis and treatment for patients for which few or no alternatives exist, as is the case in Alzheimer’s. An effective biomarker may help bring a successful drug for Alzheimer’s disease to the market.

Image by ANADMAN BVBA/Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.